Reduced expression of chemerin is associated with poor clinical outcome in acute myeloid leukemia
PDF | HTML | How to cite
Metrics: PDF 1089 views | HTML 1579 views | ?
Jing Zhang1,2, Jiao Zhou1,2, Xi Tang1,2, Ling-Yu Zhou1,2, Ling-Ling Zhai1,2, Minse Evola-Deniz Vanessa1, Jing Yi1,2, Yun-Yun Yi1,2, Jiang Lin1, Jun Qian2 and Zhao-Qun Deng1
1Department of Laboratory Center, The Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, Jiangsu, People’s Republic of China
2Department of Hematology, The Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, Jiangsu, People’s Republic of China
Zhao-Qun Deng, email: [email protected]
Jiang Lin, email: [email protected]
Keywords: chemerin, diagnosis, prognosis, acute myeloid leukemia, biomarker
Received: August 01, 2017 Accepted: August 29, 2017 Published: September 30, 2017
Chemerin is dysregulation in numerous solid cancers. However, only little is known about the role of chemerin in acute myeloid leukemia (AML). In this study, we aimed to investigate the expression and clinical significance of recently described chemerin in acute myeloid leukemia (AML). The expression of chemerin in 149 patients with de novo AML and 35 normal controls was quantified by Real-time quantitative PCR (RQ-PCR). Chemerin was down-expressed in AML compared with controls (P=0.042). A receiver operating characteristic (ROC) curve revealed that chemerin expression could differentiate patients with AML from control subjects (AUC=0.611, 95% CI: 0.490-0.732; P=0.042) respectively. The cohort of AML patients was divided into two groups according to the cut-off value of 0.0826 (79% sensitivity and 54% specificity, respectively). In addition, the AML patients with low chemerin expression had significantly shorter overall survival (OS) than those with high chemerin expression (P=0.049). Moreover, multivariate survival analysis confirmed that chemerin was an independent prognostic factor for AML patients. In conclusion, downregulation of chemerin might be a useful diagnostic and prognostic factor for AML patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.